Navigation Links
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Date:12/15/2007

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Interim results of the Phase II XeNA (Xeloda in NeoAdjuvant) trial suggest that the combination of oral Xeloda(R) (capecitabine) and Taxotere(R) (docetaxel), with the addition of Herceptin(R) (trastuzumab) in HER2-positive patients, may be an active and well-tolerated neoadjuvant (pre-surgical) treatment option for women with invasive breast cancer. These data were presented today at the San Antonio Breast Cancer Symposium (SABCS).

In the multi-center, open-label trial -- designed to investigate the activity of a short non-anthracycline-based preoperative treatment for early breast cancer in both HER2-negative and HER2-positive patients -- promising results were achieved after only four cycles of pre-surgical treatment as compared to the standard eight cycles. The majority of the 156 patients responded to the Xeloda-based therapy regardless of HER2 status, and both patient groups experienced a clinically significant reduction in tumor size.

"These early XeNA trial results highlight the potential of the Xeloda/Taxotere combination, with Herceptin for HER2-positive patients, to provide an effective and safe treatment option in a shorter period of time before surgery among patients with invasive breast cancer," said Dr. Debu Tripathy, lead investigator of the XeNA trial and Professor of Medicine and Director of the Komen/UT Southwestern Breast Cancer Research Program at the University of Texas Southwestern Medical Center at Dallas. "While these findings warrant additional studies, the real-world impact of the reduction in tumor size could translate into the difference between a lumpectomy instead of a more drastic mastectomy."

In the interim analysis, following four treatment cycles, the combination of Xeloda, Taxotere and Herceptin in HER2-positive patients resulted in a 73 percent clinical response rate (complete and partial response) and a 50 percent pathologic response (pathologic complete response, w
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS)
2. Promising drug combination may help those with ocular melanoma that has spread
3. Combination therapy reverses effects of portal hypertension in rats
4. Combination vaccines okay for infants, study shows
5. Antidepressants and painkillers - a dangerous combination
6. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
7. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
8. Drug combination might offer hope for patients deadly brain tumors
9. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
10. Combination targets: some drugs may work best when they work together
11. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. Jian-Dong Li, ... University and a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has ... middle-ear infections. , The grant from the National Institute on Deafness and Other ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... the manufacturers of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for ... District of West Virginia on June 26th, the Court rejected the Plaintiff’s ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... of liberty. Americans have been arguing over laws governing sexuality since the first ... as a forthcoming historical comparative biography by Cindy Safronoff reveals. Crossing Swords: Mary ...
(Date:7/1/2015)... ... July 01, 2015 , ... SuiteRx, innovative leaders in ... compounding pharmacy operations, announces the most recent positioning of SuiteRx CEO, Nicholas Zener ... event at the Venetian Las Vegas, Nevada. During this event, SuiteRx will ...
(Date:7/1/2015)... ... July 01, 2015 , ... A healthy eating ... chickens and eggs. Eating organic foods and products can help limit the exposure ... friendly than production chicken farming. Choosing home raised chickens and eggs that do ...
Breaking Medicine News(10 mins):Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 2Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 3Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 4Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 2Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 4Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2
... , LOS ANGELES , Jan. ... there is a new ray of hope in the form of a ... and the ANTI AGING Institute of California known as ... of menopause with ingredients like green tea extract, pomegranate extract and chromium ...
... ... joined Summit Medical Group in Internal Medicine and Occupational Health. , ... Berkeley Heights, N.J. (Vocus) January 18, ... Medicine and Occupational Health. , , , , ,Dr. Chervenak earned her B.A. summa ...
... ... knowledge of various email server environment such as Exchange, Domino, GroupWise, along with all ... that delivers high performance bi-directional mail server migration, archiving, stubbing when necessary, along ... , ...
... ... an Aprima reseller , ... Dallas (Vocus) January 17, 2010 -- Aprima Medical Software , a leading ... today announced that Advanced Foot and Ankle Specialists of Brandon, Florida, a ...
... genetic variants that influence blood glucose regulation, insulin resistance, ... of European descent. Five of the newly discovered ... the most common form of diabetes. ... of Glucose and Insulin Related Traits Consortium (MAGIC), provide ...
... ... is based on 30 year old technology. Although this simple test is ... heart attack patients have low to moderate cholesterol levels. An affordable, direct access ... PLAC Test for only $79. The PLAC Test helps identify hidden" cardiovascular risk ...
Cached Medicine News:Health News:100% Natural Remedy for Menopause Symptoms Offers Guaranteed Satisfaction 2Health News:100% Natural Remedy for Menopause Symptoms Offers Guaranteed Satisfaction 3Health News:Summit Medical Group Welcomes Rene Schreiber Chervenak, M.D. 2Health News:MessageSolution Releases Enterprise Migration System, the First Multi-Functional Migration/Archiving System in the Market, at IBM's Lotusphere 2010 2Health News:MessageSolution Releases Enterprise Migration System, the First Multi-Functional Migration/Archiving System in the Market, at IBM's Lotusphere 2010 3Health News:MessageSolution Releases Enterprise Migration System, the First Multi-Functional Migration/Archiving System in the Market, at IBM's Lotusphere 2010 4Health News:Advanced Foot and Ankle Specialists Improves Efficiency, Workflow With Aprima Electronic Health Record 2Health News:Advanced Foot and Ankle Specialists Improves Efficiency, Workflow With Aprima Electronic Health Record 3Health News:Advanced Foot and Ankle Specialists Improves Efficiency, Workflow With Aprima Electronic Health Record 4Health News:Newly identified genes influence insulin and glucose regulation 2Health News:Newly identified genes influence insulin and glucose regulation 3Health News:The PLAC Test is Now Available at ANY LAB TEST NOW North Dallas 2
(Date:7/1/2015)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... in New York, NY on ... James Sapirstein , Chief Executive Officer, ... his live presentation and will be available to participate ...
(Date:7/1/2015)... Pa. , July 1, 2015 Precyse, ... and education, announced today that, as part of its ... an agreement to be acquired by investment firm Pamplona ... private equity investors, Altaris Capital Partners and NewSpring Capital, ... in 1999, has assisted nearly 5,000 healthcare facilities and ...
(Date:7/1/2015)... DUBLIN , June 24, 2015 ... has announced the addition of the "2015 ... to their offering. This new 175-page ... market segments, including diabetes (strips and meters), pregnancy, ... dynamics, size, growth, regulatory requirements, technologies, and competitive ...
Breaking Medicine Technology:ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 32015 Strategies in the Home/Self Testing Market 2
... Instruments Incorporated (TI) (NASDAQ: TXN ) today ... with five new fully integrated AFEs for portable biopotential ... AFEs are the first to offer 16- and 24-bit ... power consumption by more than 94 percent compared to ...
... April 4, 2012  UCB (Euronext Brussels: UCB) and Amgen ... of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical ... "We look forward to working with UCB on ... Harper, M.D., executive vice president of Research and Development ...
Cached Medicine Technology:TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 2TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 3TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 4TI introduces industry's first single- and dual-channel, 16- and 24-bit ECG/EEG analog front ends 5UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 2UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 3UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 4UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 5UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 6UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis 7
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: